CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Desvenlafaxine succinate

Last Updated: March 5, 2009
Result type: Reports
Project Number: SR0159-000
Product Line: Reimbursement Review

Generic Name: Desvenlafaxine succinate

Brand Name: Pristiq

Manufacturer: Wyeth Canada

Therapeutic Area: Depressive, Major Disorder (MDD)

Indications: Depressive, Major Disorder (MDD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 23, 2009

Recommendation Type: Do not list